Lv11
40 积分 2023-08-03 加入
A First-in-Class JAK/ROCK Inhibitor, Rovadicitinib, for Glucocorticoid-Refractory or -Dependent Chronic GVHD
5小时前
求助中
A First-in-Class JAK/ROCK Inhibitor, Rovadicitinib, for Glucocorticoid-Refractory or -Dependent Chronic GVHD
5小时前
已关闭
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
16天前
已完结
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis
3个月前
已关闭
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis
3个月前
已关闭
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis
3个月前
已关闭
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis
3个月前
已关闭
Clinical pharmacokinetic characteristics of Jaktinib in subjects with hepatic impairment in a phase I trial
4个月前
已完结
[Consensus on the clinical diagnosis, treatment, and prevention of cancer related anemia in China (2023 edition)]
4个月前
已完结
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
